Northern Trust Corp E Ffector Therapeutics, Inc. Transaction History

Northern Trust Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.37 - $0.69 $45,879 - $85,558	123,998 Added 336.82%	160,812 $75,000
Q3 2023 Nov 13, 2023	BUY	$0.49 - $0.88 $5,302 - $9,522	10,821 Added 41.63%	36,814 $22,000
Q2 2022 Aug 12, 2022	BUY	$1.3 - $3.84 $12,022 - $35,512	9,248 Added 55.23%	25,993 $37,000
Q1 2022 May 13, 2022	BUY	$3.85 - $8.2 $338 - $721	88 Added 0.53%	16,745 $67,000
Q4 2021 Feb 08, 2022	BUY	$5.71 - $13.15 $95,111 - $219,039	16,657 New	16,657 $138,000

6.53M

Ticker EFTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,452,800
Description
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-sma...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.